Skip to Main

André Kronimus is Boston Consulting Group’s global topic leader for corporate finance and strategy in health care (biopharma and medtech) and chemicals. He is a member of the firm’s global Health Care and Corporate Finance and Strategy practice leadership teams and coleads BCG's Corporate Finance Task Force in Europe. He is also a core member of the Industrial Goods practice, with a particular focus on the chemical and agrochemical industry.

Since joining BCG in 2003, André has worked extensively in mergers and acquisitions in the US, Europe, and Asia, on both the buy and sell sides.

He has also worked with numerous clients on a wide range of corporate development topics, including corporate and portfolio strategy, growth strategy, and industry landscaping, plus finance organization and processes, primarily in the biopharma, medtech, and chemical sectors. André frequently advises private-equity funds on due diligence and portfolios.

Before joining BCG, André worked as a research and teaching assistant in finance at the WHU Otto Beisheim School of Management.

AREAS OF EXPERTISE

EDUCATION

  • PhD, finance, WHU Otto Beisheim School of Management
  • MBA, WHU Otto Beisheim School of Management

Publications and Videos

" "

Tackling the Talent Challenge in Biotech Acquisitions

To retain target biotech company employees—arguably as vital to success as the pipeline being acquired—biopharmas need talent strategies that focus on three key areas.
Biopharma Carve-Outs Are Tricky - rectangle

Biopharma Carve-Outs Are Tricky. Here’s How to Get Them Right.

Through carve-outs, companies can create value, streamline portfolios, and reduce complexity. But the ultimate success of a deal hinges on focused, proactive execution.
Unleashing the Innovation Power of Alliances - rectangle

Unleashing the Innovation Power of Alliances

More companies are forging strategic alliances as they seek competitive advantage. Here’s what they must do to build and manage them successfully.
Building-Effective-Business-Development-in-Pharma-rectangle.jpg

Building Effective Business Development in Pharma

Teams often struggle to execute external licensing agreements and M&A transactions that can supplement internal innovation and revenue. Six factors can enhance performance.
us-tax-2880x1620-tcm9-184904.jpg

The Impact of US Tax Reform on Corporate Strategy and M&A

The new US tax law is likely to reshape corporate portfolios, provided buyers and sellers can overcome the new big uncertainty that the regime introduces—its own duration.
cultivating-the-pearl-1694x950-tcm9-62276.jpg

Creating Value from Midsize Biopharma Acquisitions

Although small in scale relative to the acquiring company, midsize acquisitions are becoming important to creating value in the biopharmaceutical industry.
heath-care-value-creators-2014-1694x950-tcm9-83862.jpg

The 2014 Health-Care-Services Value Creators Report

The global health-care industry is at an inflection point, and services companies must take decisive steps if they are to continue creating value for their investors.
medtech-vc-2013-1694x950-tcm9-90314.jpg

The 2013 Medtech Value Creators Report

Having outperformed the overall capital market in recent years, medical-technology companies now face sizable shifts in the health care environment that will dictate fundamental changes in their operating model.
biopharma-vc-2013-1694x950-tcm9-90396.jpg

The 2013 Biopharma Value Creators Report

The health care industry is changing, and biopharmaceutical companies need to take decisive action to ensure that their recent strong value-creation performance remains sustainable.
using-ma-175x175-tcm9-169813.jpg

Pharmaceuticals: Using M&A as a Cure

M&A is increasingly necessary, but extracting value is more difficult than it was in the past. What should pharmaceutical companies do?